cAMPfield

cAMPfield Therapeutics is a clinical-stage biopharmaceutical company focused on developing well-tolerated and highly effective oral medicines for immune-mediated inflammatory diseases, including inflammatory bowel disease. cAMPfield's lead candidate is prifemilast, a potentially best-in-class PDE4 inhibitor for the treatment of IBD, in-licensed from Newsoara Biopharma and the company is initiating global Phase 2 trials in moderate-to-severe ulcerative colitis and Crohn's disease.